Condition: Epilepsy, Generalized · Epilepsy, Absence · Sponsor: NeuroPro Therapeutics, Inc.
This study will compare the effect of NPT 2042 and placebo in subjects with GGE on the frequency and duration of electroencephalographic absence seizures, separated by a 14-day washout period. The study will be a single-center, double-blind, crossover study with subjects receiving either NPT 2042 BID orally or matching placebo BID in each of two treatment periods. Two doses of NPT 2042 will be evaluated.
This description comes directly from the study's public registry record.
JoAnn Giannone · 9196371566 · joann@npt.io
Charles Moser · chuckmoser.nlc@gmail.com
Always discuss trial participation with your own doctor first.
| Clinical Trials, Inc. (CTI) | Little Rock, Arkansas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06769659